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The increased glucose metabolism in cancer cells is required to fulfill their high energetic and biosynthetic
demands. Changes in the metabolic activity of cancer cells are caused by the activation of oncogenes or loss of
tumor suppressors. They can also be part of the metabolic adaptations to the conditions imposed by the tumor
microenvironment, such as the hypoxia response. Among the metabolic enzymes that are modulated by these
factors are the 6-phosphofructo-2-kinase/fructose 2,6-bisphosphatases (PFKFBs), a family of bifunctional enzymes
that control the levels of fructose 2,6-bisphosphate (Fru-2,6-P2). This metabolite is important for the dynamic
regulation of glycolytic flux by allosterically activating the rate-limiting enzyme of glycolysis phosphofructokinase-1
(PFK-1). Therapeutic strategies designed to alter the levels of this metabolite are likely to interfere with the
metabolic balance of cancer cells, and could lead to a reduction in cancer cell proliferation, invasiveness and
survival. This article will review our current understanding of the role of PFKFB proteins in the control of cancer
metabolism and discuss the emerging interest in these enzymes as potential targets for the development of
antineoplastic agents.
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Cancer cells alter their metabolism to support continuous
cell growth and proliferation in a challenging environ-
ment. Many cancer cells display high rates of aerobic gly-
colysis, a phenomenon historically known as the Warburg
effect [1]. Oncogenes such as RAS, SRC and MYC have
been found to enhance glycolysis by increasing the expres-
sion of glucose transporters and glycolytic enzymes [2,3].
Moreover, hypoxia-inducible factor (HIF), a key transcrip-
tion factor that regulates the adaptation of cells to hypoxic
conditions and is frequently deregulated in cancer, also
induces the expression of genes involved in glycolysis [4].
It has therefore been concluded that genetic alterations
that cause tumorigenesis are also responsible for the regu-
lation of glycolysis in cancer cells (reviewed in [5]).
Among the glycolytic enzymes that are induced in cancer
are the 6-phosphofructo-2-kinase/fructose 2,6-bisphospha-
tases (PFK-2/FBPase-2), a family of bifunctional enzymes* Correspondence: almut.schulze@cancer.org.uk
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distribution, and reproduction in any mediumthat control the levels of fructose 2,6-bisphosphate (Fru-
2,6-P2). These enzymes catalyze the synthesis of Fru-2,6-P2
from fructose 6-phosphate (Fru-6-P) and ATP, a reaction
that occurs at the N-terminal 6-phosphofructo-2-kinase
domain (Figure 1). Conversely, PFK-2/FBPase-2 also cata-
lyzes the reverse reaction, the hydrolysis of Fru-2,6-P2 to
fructose 6-phosphate (Fru-6P) and inorganic orthophos-
phate at the C-terminal fructose 2,6-bisphosphatase do-
main (Figure 1). Both catalytic domains are present in the
same polypeptide that functions within a homodimeric
protein complex [6,7].
Fru-2,6-P2 is a powerful allosteric activator of phospho-
fructokinase 1 (PFK-1), the enzyme that controls one of
the most critical steps of glycolysis [8-11]. The tetrameric
enzyme PFK-1 catalyzes the conversion of Fru-6-P and
ATP to fructose 1,6-bisphosphate and ADP (Figure 1).
Interestingly, PFK-1 activity is inhibited by ATP, citrate or
fatty acids, thereby adjusting glycolytic activity to envi-
ronmental conditions and cellular metabolic demands. In-
deed, inhibition of PFK-1 by ATP is part of the negative
feedback loop that limits glycolytic flux under aerobictral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,






















Figure 1 PFK-2/FBPase-2 control of glycolysis and
gluconeogenic pathways. Overview of glycolysis and
gluconeogenesis. Enzymes: phosphofructokinase (PFK-1), fructose
1,6-bisphosphatase (FBPase), 6-phosphofructo-2-kinase/fructose
2,6-bisphosphatases (PFK-2/FBPase-2), pyruvate kinase (PK). Fructose
2,6-bisphosphate is an activator of PFK-1 and inhibitor of FBPase.
Fructose 1,6-bisphosphate is an activator of PK. The rest of the
enzymes and cofactors have been omitted for simplicity.
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PFK-1 by Fru-2,6-P2 relieves this inhibition [12]. Increased
levels of Fru-2,6-P2 would therefore allow transformed
cells to maintain a high glycolytic flux despite the presence
of ATP. However, unlike PFK-1, PFK-2 is not affected by
ATP concentrations. Interestingly, inorganic orthophos-
phate stimulates PFK-2, while phosphoenolpyruvate and
citrate can inhibit it. PFK-2 activity is also inhibited by sn-
glycerol 3-phosphate, which is competing with Fru-6-P for
binding to the catalytic site [13]. sn-glycerol 3-phosphate
also stimulates the FBPase-2 activity, and is capable of par-
tially reversing the inhibition of the enzyme by Fru-6-P
[13]. GTP also stimulates the FBPase-2 activity [14].
Fru-2,6-P2 not only controls the PFK-1 reaction but also
controls the reverse reaction in the gluconeogenic pathway
by inhibiting fructose 1,6-bisphosphatase (FBPase) [8].
It is clear that by modulating the levels of Fru-2,6-P2,
PFK-2/FBPase-2 enzymes could be crucial players in the
regulation of the metabolic activity of cancer cells.The PFKFB genes
There are several PFK-2/FBPase-2 isoenzymes in mam-
mals, which are encoded by four different genes, PFKFB1
to PFKFB4, located on different chromosomes (Figure 2).
Their genomic organization reveals how each gene codes
for several isoforms by differential splicing, and for even
more mRNAs due to the presence of several promoters
and 5’ non-coding exons. Despite the high sequence hom-
ology within their core catalytic domains, different PFK-2/
FBPase-2 isoenzymes display distinct regulatory and kin-
etic properties. Importantly, it has been shown that cells
can coexpress several PFK-2/FBPase-2 isoforms suggesting
that different isoenzymes cooperate in the regulation of
Fru-2,6-P2 levels [15,16].
PFKFB1
The PFKFB1 gene contains 17 exons and encodes 3 diffe-
rent mRNAs (L, M and F) that are derived from different
promoters and differ only within their first exon [17,18].
The first exon of the L isoform (exon 1L, L-PFK2) codes
for 32 amino acids and gives rise to a protein that carries
a serine residue at position 32, which can be targeted by
phosphorylation (discussed in detail below). This isoform
is expressed in liver, skeletal muscle and white adipose tis-
sue. The first exon of the M isoform (exon 1M, M-PFK2)
only codes for nine amino acids, none of which provides a
substrate for phosphorylation. The M promoter targets
expression of this isoform to skeletal muscle and white
adipose tissue. Promoter F generates the F isoform (non-
coding 1Fa and 1Fb and part of 1M exon, F-PFK2) that is
expressed in fibroblasts and fetal tissue.
PFKFB2
The PFKFB2 gene encodes the heart isoenzyme (H-PFK2).
The PFKFB2 gene encodes four different mRNAs that are
derived from different promoters and that vary only in
non-coding sequences at the 5’ end [19,20]. The resulting
proteins thus differ in their C-terminal amino acid se-
quence [20]. Alternative splicing of the terminal exon 15
results in its two main isoforms (58 and 54 kDa). However,
it is not known how these different 5’ ends relate to the
three mRNAs (H1, H2 and H4) that encode the 58-kDa
isoform or the H3 mRNA that encodes the 54-kDa
isoform.
PFKFB3
The PFKFB3 gene codes for an isoenzyme originally
cloned from bovine brain [21] and from human placenta
[22]. It contains at least 19 exons and has been shown to
generate at least 6 different transcripts by alternative spli-
cing. The resulting polypeptides differ in the length of
their C-terminal variable regions that are encoded by the
last seven exons. Alternative splicing of exon 15 generates
the two main isoforms that differ by a short C-terminal
Figure 2 Relative activity of 6-phosphofructo-2-kinase (PFK-2)/fructose 1,6-bisphosphatase (FBPase-2). Properties of the PFK-2/FBPase-2
enzymes. Information on chromosomal location and relative enzymatic activity of the different isoforms has been taken from Okar et al. Trends
Biochem Sci (2001) [7].
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the inducible PFK2 (i-PFK2, 16 exons) isoforms [23]. Four
additional splice variants have also been reported in
human brain [24].
PFKFB4
The PFKFB4 gene encodes the testes isoenzyme (T-PFK2),
since it was originally identified in testes [25]. The
PFKFB4 gene contains at least 14 exons, and several splice
variants of the PFKFB4 mRNA have been identified not
only in testes but also in different rat tissues [26]. These
include transcripts carrying deletions or inserts within the
FBPase-2 region as well as some with varying length and
amino acid sequence of the C-terminal part. However, the
PFK-2 catalytic domains are identical in all variants. This
could indicate a possible role of different PFKFB4 splice
variants in cell-specific and/or tissue-specific regulation of
glycolysis and requires further investigation.
TIGAR: a PFK-2/FBPase-2-like enzyme
TIGAR (C12orf5), for ‘TP53-Inducible Glycolysis and
Apoptosis Regulator’, shows functional similarities to the
bisphosphatase activity of PFK-2/FBPase-2 s [27]. Al-
though the overall sequence similarity between TIGAR
and FBPase-2 is relatively weak, the regions in the
FBPase-2 domain that have previously been identified
as essential for catalytic activity are well conserved in
TIGAR.
Differential PFK-2/FBPase-2 activities
The structural organization of the different PFK-2/
FBPase-2 isoenzymes is highly similar, with the kinase
and bisphosphatase domains in the center flanked by
regulatory regions (Figure 3). The sequence of the cata-
lytic core is highly conserved while the N-terminal and
C-terminal extremes of the proteins show more diver-
gence, being where the regions that modulate the kinase
and bisphosphatase activities are located. The differences
in kinase and bisphosphatase activities between thedifferent isoenzymes are presumably caused by struc-
tural variations within these regulatory regions.
6-Phosphofructo-2-kinase/fructose 2,6-biphosphatase 1
(PFKFB1) and PFKFB2 seem to have similar relative kinase
and bisphosphatase activities (Figure 2) [7]. In contrast,
PFKFB3 has a substantially higher kinase activity and
strongly favors the formation of Fru-2,6-P2, resulting in an
enhanced glycolytic rate [7]. The activities of PFKFB4 are
again more balanced, with the bisphosphatase activity being
slightly higher [7]. However, since the different PFK-2/
FBPase-2 enzymes are also regulated by post-translational
modifications (discussed below), their relative kinase and
bisphosphatase activity could vary according to the cellular
context.
Post-translational modifications of PFK-2/FBPase-2
enzymes
Several PFK-2/FBPase-2 isoforms are subject to post-
translational modifications that modulate the relative acti-
vities of their catalytic domains. This places the production
of Fru-2,6-P2 under the control of cellular signaling path-
ways and facilitates the regulation of glycolytic activity in
response to extracellular stimuli such as hormones or
growth factors. Therefore, Fru-2,6-P2 plays an important
role in the adaptation of organisms, tissues within them
and to changes in their environmental or metabolic state.
The liver, muscle and fetal isoforms of PFKFB1 (L-PFK2,
M-PFK2 and F-PFK2 respectively) are transcribed from
the same gene, but only L-PFK2 contains a serine residue
in position 32 of its C-terminal regulatory domain [6]
(Figure 3). This is consistent with its specific physiological
role as liver cells need to modulate Fru-2,6-P2 levels to fa-
cilitate the production of glucose to fulfill the metabolic
demand of other tissues. In response to glucagon, cyclic
AMP-dependent protein kinase (PKA) phosphorylates
Ser32 in the liver isoform of PFKFB1, leading to inactiva-
tion of its PFK-2 activity while activating its FBPase-2
function. This decreases glycolytic flux while increasing
gluconeogenesis in liver cells [28].
Figure 3 Domain organizations and phosphorylation of 6-phosphofructo-2-kinase (PFK-2)/fructose 1,6-bisphosphatase (FBPase-2)
isoenzymes. The N-terminal PFK-2 domain is shown in red, the C-terminal FBPase-2 domain is shown in blue and the regulatory domains are
shown in green. Phosphorylation sites and the kinases responsible of their phosphorylation are indicated on each main isoforms. The domain
structure of human PFK-2/FBPase-2 enzymes is based on Rider et al. Biochem J (2014) [10].
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in its kinase activity, phosphorylation of the cardiac iso-
form, known as H-PFK2 (PFKFB2), results in an increase
in this activity. Insulin stimulates glycolysis in the heart by
increasing glucose transport and activating H-PFK2. Two
serine residues, Ser466 and Ser483, within the C-terminal
regulatory domain of PFKFB2 can be phosphorylated by
protein kinase B (Akt/PKB) in response to insulin [29]
(Figure 3). Thus, expression of an insulin-dependent PFK2
in the heart could be involved in directing the increased
levels of glucose-6-phosphate, that result from the insulin-
stimulated glucose transport, towards the synthesis ofpyruvate [30]. Adrenalin promotes phosphorylation of the
same sites by PKA and also stimulates glycolysis [31].
However, the physiological significance of phosphorylation
of Ser84, Ser466 and Thr475 of H-PFK2 by protein kinase
C (PKC) is not completely understood. It seems that phos-
phorylation of Ser466 or Thr475 does not change the
enzyme activity. This might be due to the fact that the
phosphorylation at Ser84 possibly counteracts the effects of
phosphorylation at the activating C-terminal sites [31,32].
Activation of the AMP-activated protein kinase (AMPK)
during ischemia leads to phosphorylation of H-PFK2
Ser466 [33], which increases the levels of Fru-2,6-P2 and
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phorylation of Ser466 and Ser483 in the 58-kDa isoform of
H-PFK2 (PFKFB2) increases its affinity to Fru-6-P, whereas
dephosphorylation of the same residues promotes its
FBPase-2 activity [34]. Interestingly, these phosphorylation
sites are absent from the 54-kDa isoform indicating that
this isoform may have an overall reduced kinase activity
and could be less responsive to cellular signaling processes
(Figure 3). It is also possible that the two splice variants
have opposite functions in the regulation of glycolysis.
Both the ubiquitous (u-PFK2) and inducible (i-PFK2)
isoforms of PFKFB3 can be phosphorylated by AMPK at
Ser461 within their C-terminal regulatory domain. Phos-
phorylation by AMPK activates the PFK-2 activity. This
site is equivalent to Ser466 in the 58-kDa isoform of
H-PFK2 [33,35], which is phosphorylated in response to
insulin. It would be interesting to investigate whether
the same occurs in PFKFB3. Ser461 can also be phos-
phorylated by PKC and PKA [36] making it responsive
to multiple external signals. As this region is sensitive to
alternative splicing, the structural configuration around
this site may vary between different splice variants.
Although the functional consequences of having diffe-
rent C-terminal splice variants of PFKFB3 are unknown,
an examination of their activity would be useful to fur-
ther understand the regulation of this isoenzyme. Inter-
estingly, the activity of PFKFB3 is also regulated by
modulation of protein stability. PFKFB3, but not the
other isoenzymes, contains a KEN box that is recognized
by the anaphase-promoting complex/cyclosome (APC/
C-cdh1), an E3 ubiquitin ligase complex that plays an es-
sential role in G1 phase and mitosis through the degrad-
ation of several cell cycle proteins [37]. The regulatory
component of this complex, Cdh1, has been shown to be
downregulated during malignant progression in a murine
B lymphoma cell line [38] and mice heterozygous for cdh1
are more susceptible to spontaneous tumor formation
[39]. This decrease in APC/C-Cdh1 activity leads to the
accumulation of PFKFB3 and enhances the glycolytic flux
in malignant cells [37], demonstrating that proliferation
and the induction of aerobic glycolysis are both essential
components of neoplastic transformation.
To date, no post-translational modifications have been
described for PFKFB4, making this isoform potentially
less dynamic. However, it is likely that PFKFB4 activity is
modulated in response to changes in the concentration
of substrate and product or the presence of activators or
inhibitors.
PFK-2/FBPase-2 enzymes in hypoxia
Hypoxia is an important component of the tumor micro-
environment and can regulate several processes important
for tumor formation, including tumor angiogenesis and
metastasis formation. Hypoxia also regulates the metabolicactivity of cancer cells and induces glycolysis. Adaptation
to hypoxic conditions is largely mediated by HIF, a tran-
scription factor that regulates a distinct transcriptional
program [40]. HIF is activated in hypoxia through the
stabilization of its regulatory α subunits and induces the
expression of its target genes, including glucose transpor-
ters and glycolytic enzymes. Notably, HIF can be active in
cancer cells even under non-hypoxic conditions, thereby
contributing to the enhanced glycolytic activity observed
in cancer cells [41,42].
Interestingly, both PFKFB3 and PFKFB4 are known to
be components of the HIF-mediated response to hypoxia.
PFKFB3 is a hypoxia-inducible gene that is stimulated
through the interaction of HIF-1α with a consensus HRE
within its promoter region [43]. In addition, hypoxic in-
duction of PFKFB4 is mediated by a hypoxia response
element (HRE) in the promoter region of the PFKFB4
gene [44]. Other studies have demonstrated that PFKFB1,
PFKFB2, PFKFB3 and PFKFB4 mRNAs are induced in
organs that are exposed to hypoxic conditions, although
PFKFB3 presented the highest induction in this study
[16].
Overall, the finding that PFK-2/FBPase-2 enzymes are
induced in hypoxia suggests their important role in the
glycolytic phenotype of cancer cells. In this context they
would enable metabolic adaptation to the hypoxic envi-
ronment promoting cell survival.PFK-2/FBPase-2 enzymes in cancer
Several studies have demonstrated that some cancer cell
lines produce markedly elevated levels of Fru-2,6-P2
when compared to non-malignant cells [45-47]. One of
the important functions of enhanced glucose uptake and
glycolysis in cancer cells is to generate metabolic inter-
mediates that are important for cell growth and survival
(Figure 4). Metabolism of glucose through the oxidative
or non-oxidative arms of the pentose phosphate pathway
(PPP) generates ribose-5-phosphate, a key intermediate
in nucleotide biosynthesis. The oxidative arm of the PPP
also generates nicotinamide adenine dinucleotide phos-
phate (NADPH), which is required for nucleotide and
fatty acid biosynthesis. Moreover, NADPH is also im-
portant for the maintenance of cellular redox balance.
The enhanced metabolic activity of cancer cells can
result in increased levels of reactive oxygen species
(ROS) and to oxidative damage. ROS-induced-damage
can be repaired due to NADPH providing the reducing
power for the glutathione (GSH) and thioredoxin (TRX)
systems [48]. In this regard, it is hypothesized that the
fructose 2,6-bisphosphatase activities of the PFK-2/
FBPase-2 enzymes could also allow accumulation of
glycolytic intermediates for biosynthetic processes and























Figure 4 Role of 6-phosphofructo-2-kinase (PFK-2)/fructose 1,6-bisphosphatase (FBPase)-2 in the balance between glycolytic flux and
redox regulation. Glucose-6-phosphate fulfills glycolysis, glycogen synthesis and pentose phosphate pathways. The scheme shows how the PFK-2 or
the FBPase-2 activity could be crucial in controlling the balance between glycolytic flux and redox regulation by the pentose phosphate pathway for
nicotinamide adenine dinucleotide phosphate (NADPH) production. Enzymes: phosphofructokinase (PFK-1), phosphofructokinase 2/fructose
2,6-bisphosphatase (PFK-2/FBPase-2), TIGAR (FBPase-2 activity). Fructose 2,6-bisphosphate is an activator of PFK-1 and inhibitor of FBPase.
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formed cells to maintain a high glycolytic flux, several
studies have investigated the potential roles of the differ-
ent PFK-2/FBPase-2 enzymes in cancer metabolism. All
PFKFB mRNAs have been reported to be overexpressed in
the human lung cancers when compared with correspond-
ing normal tissues [49].
However, there has not been a great deal of cha-
racterization of the possible role of PFKFB1 in cancer to
date. Expression of the fetal isoform of PFKFB1 has been
shown to be induced in proliferating cells resulting in an
increased glycolytic rate [18].
PFKFB2 has been shown to be upregulated as a conse-
quence of the transcriptional changes orchestrated by the
androgen receptor in prostate cancer cells, with possible
control through the AR-CAMKII-AMPK signaling path-
way [50]. Moreover, expression of PFKFB2 is induced in
LNCaP prostate cancer cells after androgen treatment by
the direct recruitment of the ligand-activated androgen
receptor to the PFKFB2 promoter [51]. Depletion of
PFKFB2 expression resulted in a reduced glucose uptake
and lipogenesis, suggesting that the induction of de novo
lipid synthesis by androgen requires the transcriptional
upregulation of PFKFB2 in prostate cancer cells [51].
Due to its increased kinase activity, PFKFB3 has been
suggested as the isoenzyme most likely to contribute to
the high glycolytic activity observed in transformed cells
[52]. The inducible isoform of PFKFB3 (i-PFK2) has been
reported to be overexpressed in several human cancer cell
lines if compared to normal cells, and has been shown to
be required for tumor cell growth in vitro and in vivo [53].
PFKFB3 mRNA is induced in hypoxia though a HIF-1α
dependent mechanism in cancer cell lines from differenttissues including glioblastoma, gastric and pancreatic can-
cer [54]. In contrast, the PFKFB3 gene, in particular the
i-PFK2 splice variant, has been recently shown to be a tar-
get for loss of heterozygosity on 10p14-p15, which is com-
mon in high-grade gliomas [55]. A reduction of total
PFKFB3 level by allelic deletion might lead to decreased
Fru-2,6-P2 levels, which might result in decreased rate of
glycolysis: a hallmark of glioblastomas [56,57]. However,
other types of cancers, such as breast, colon, lung, pancre-
atic, prostatic and ovarian, express high levels of PFKFB3
protein relative to the non-malignant adjacent tissue [58].
Furthermore, PFKFB3 protein is highly phosphorylated at
Ser461, the consensus site for AMPK, PKA and PKC, in
colon and breast carcinoma compared to epithelial cells
from normal tissue, suggesting enhanced PFK-2 activity in
cancer [35]. It has been shown recently that elevated ex-
pression of the tumor suppressor phosphatase and tensin
homolog (PTEN) negatively impacts on glycolysis by pro-
moting APC/C-Cdh1 activity resulting in the downregula-
tion of the PFKFB3 protein [59]. Given that PTEN is
frequently mutated or deleted in human cancer, it would
be interesting to further investigate the correlation bet-
ween loss of PTEN and a possible increase in PFKFB3
protein, which could then impact on glycolytic activity.
Moreover, silencing of PFKFB3 has been reported to de-
crease Fru-2,6-P2 levels and glycolytic rate in HeLa cells,
thereby reducing cell viability and anchorage-independent
growth [60]. Interestingly, introduction of oncogenic
H-rasV12 promotes anchorage-independent growth of pri-
mary lung fibroblasts derived from PFKFB3+/+ but not
from PFKFB3+/− mice [15]. PFKFB3+/− fibroblasts have
reduced levels of Fru-2,6-P2 compared to wild-type cells.
This might expose PFK-1 to the inhibitory effects of ATP
Ros and Schulze Cancer & Metabolism 2013, 1:8 Page 7 of 10
http://www.cancerandmetabolism.com//1/1/8thereby abolishing the capacity of oncogenic RAS to con-
fer the capacity for anchorage-independent growth, sug-
gesting that PFKFB3 may be a highly selective target for
the development of antineoplastic agents.
PFKFB4 expression is induced in breast, colon, lung,
gastric and pancreatic cancer cell lines [49,54,61,62].
Interestingly, it has been recently demonstrated that
PFKFB4 plays an essential role in the survival of glioma
stem-like cells [63]. Knockdown of PFKFB4 resulted in
downregulation of lactate secretion and ATP production
and ultimately induced apoptosis in these cells. This
study also demonstrated that brain cancer stem-like cells
have increased PFKFB4 mRNA expression when com-
pared to that of adult normal brain tissue, while the
mRNA of PFKFB3 is downregulated. These findings sug-
gested that PFKFB4 is the main PFK-2/FBPase-2 isoen-
zyme that regulates glycolytic flux in malignant glioma
cells. Interestingly, PFKFB4 silencing has also been
demonstrated to be detrimental for prostate cancer cell
survival [64]. Silencing of PFKFB4 resulted in increased
levels of Fru-2,6-P2 in prostate cancer cells. This led to
the conclusion that in response to PFKFB4 depletion,
metabolic intermediates are diverted towards glycolysis
and away from the oxidative arm of the PPP, resulting in
reduced levels of NADPH production. Prostate cancer
cells may then selectively rely on PFKFB4 for managing
ROS accumulation, since treatment with a ROS
scavenger rescued the viability defect in the PFKFB4-
knockdown prostate cancer cells. PFKFB4 mRNA
expression was also found to be higher in metastatic
prostate cancer when compared with primary tumors.
Notably, PFKFB4 was not only required for the survival
of prostate cancer cells, but also for other cancer cell
lines from different tissues. While the role of this isoen-
zyme in different cancer types needs further investiga-
tion, these results suggest that it could be a potential
target for cancer therapy.
The potentially opposing effects of the different PFK-2/
FBPase-2 in regulating Fru-2,6-P2 levels in some cancer
cells may seem contradictory. Further investigation in the
relationship between Fru-2,6-P2 concentration and which
isoforms are expressed in these tumors would be helpful
to understand this paradigm. However, it is likely that can-
cer cells express different levels of the different PFK-2/
FBPase-2 enzymes and even modulate the relative kinase
and bisphosphatase activity according to their metabolic
needs in a spatial and/or temporal manner. Cancer cells
may experience conditions of intermittent hypoxia due to
insufficient vascularization of some tumor areas. Under
these conditions, induction of glycolysis may be required
to support anaerobic ATP production for which the kinase
activity of PFK-2/FBPase-2 enzymes would be essential.
However, the high biosynthetic demand of rapidly prolife-
rating tumor cells also requires the production of largeamounts of NADPH and the bisphosphatase activity may
be indispensable to limit glycolytic activity and divert
metabolites for NADPH production. It is therefore pos-
sible that cancer cells regulate the activity of different
PFK-2/FBPase-2 enzymes in a tight temporal and spatial
manner to meet their metabolic demands and therefore
maintain viability.
TIGAR could also play an important role in this com-
plexity and participate in shaping the metabolic profile of
the cell. It has been demonstrated that TIGAR works as an
FBPase-2 and diverts glucose intermediates from glycolysis
into the pentose phosphate pathway [27]. Then TIGAR
promotes the production of NADPH to allow the gene-
ration of reduced glutathione to protect against ROS, and
facilitates the formation of ribose 5-phosphate for nucleo-
tide synthesis. It was also reported that overexpression of
TIGAR in cancer cells led to ROS quenching and protec-
tion from p53-mediated apoptosis as a result of genotoxic
stress and DNA damage [27]. Therefore, the reduction of
glycolytic flux through the induction of TIGAR is consis-
tent with the function of p53 as a tumor suppressor. Inte-
restingly, inhibition of the pentose phosphate pathway can
also lead to the activation of p53, suggesting the presence
of a feedback loop that can restore pentose phosphate ac-
tivity through induction of p53 and TIGAR [65]. Notably,
p53 was also shown to reduce the production of NADPH
by binding and inhibiting glucose-6-phosphate dehydro-
genase (G6PD), the first and rate-limiting enzyme of the
pentose phosphate pathway [66]. It is believed that the
increased G6PD activity may be dominant over the loss of
TIGAR induction in p53 mutant/loss cancer cells. Further-
more, TIGAR was found to be expressed in several cancer
cell lines in a p53-independent manner and therefore may
have additional roles in the survival and proliferation of
transformed cells [27].
It is clear that PFK-2/FBPase-2 enzymes and TIGAR
are important players in the control of cancer cell me-
tabolism. However, it should also be considered that
PFK-2/FBPase-2 enzymes might have other functions in
cancer cells that are unrelated to their role as glycolytic
regulators. In this context, a recent study showed that
the C-terminal domain of PFKFB3 variant 5 localizes the
enzyme to the nucleus where Fru-2,6-BP increases the
expression and activity of cyclin-dependent kinase-1
promoting cell proliferation [52].
Targeting PFK-2/FBPase-2 enzymes for cancer therapy
As outlined above, PFK-2/FBPase-2 enzymes play an im-
portant role in tumor metabolism and cancer cell survival.
Given this, it is not surprising that they have been consi-
dered as potential targets for cancer therapy. These efforts
have thus far mainly been concentrated on the inhibition
of the PFK-2 activity of PFKFB3, as it is induced by several
oncogenes as well as hypoxia and may contribute to the
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compounds have been developed to date. One of these
compounds, N-bromoacetiletanolamine phosphate, was
originally developed as a synthetic substrate analogue for
fructose bisphosphate aldolase, the glycolytic enzyme that
catalyzes the reversible conversion of fructose 1,6-
bisphosphate into dihydroxyacetone phosphate and
glyceraldehyde 3-phosphate (Figure 1). However, it was
subsequently shown to be an irreversible inhibitor of PFK-2
in several cancer cell lines [67]. Clem et al. identified a
small molecule inhibitor of PFK-2 named 3-(3-pyridinyl)-1-
(4-pyridinyl)-2-propen-1-one (3-PO) [68]. This compound
has been shown to decrease glucose uptake and Fru-2,6-P2
levels in vivo, and to suppress tumorigenic growth of breast,
leukemia and lung adenocarcinoma cells. However, due to
the strong homology of all four PFKFB proteins in their
PFK-2 domain, it is possible that 3-PO not only inhibits
PFKFB3 but also the other isoenzymes. Two additional
PFKFB3 inhibitors have been recently developed using a
structure-based approach: N4A and its derivative YN1 [69].
These compounds should have higher specificity as they
are targeted towards the fructose 6-phosphate-binding site
rather than the ATP-binding pocket. Since the activity of
these compounds towards other PFKFB proteins has not
yet been established, their antiproliferative effect on cancer
cells may not be solely ascribed to the inhibition of
PFKFB3. Consequently, it may be necessary to develop
inhibitors that are highly selective towards PFKFB3 to avoid
toxicity due to the inhibition of other PFK-2/FBPase-2
enzymes, particularly for tissues such as the liver that sup-
port metabolic homeostasis at an organismal level.
Strategies to inhibit PFK-2 activity, in particular for
PFKFB3, may be successful in reducing the high glycolytic
activity of cancer cells. However, recent evidence suggests
that the FBPase-2 activity, specifically that of PFKFB4,
may also be important for cancer cell survival [64]. Knock-
down of PFKFB4 blocked prostate cancer cell growth and
remarkably induced regression of prostate tumor xeno-
grafts, confirming that prostate cancer cells are dependent
on PFKFB4 for survival. Moreover, the requirement of
PFKFB4 for cell survival seems to be extended beyond
prostate cancer because other cancer cell lines were also
sensitive to PFKFB4 knockdown. Together, these findings
implicate PFKFB4 as a potential therapeutic target. How-
ever, no strategies for the selective inhibition of the
FBPase-2 activity have been developed to date. A major
obstacle for this approach is the general lack of unique
topological features within phosphatase domains, which
limits the specificity of binding of candidate compounds.
Despite these challenges, FBPase-2 activity may still
emerge as an important target for cancer therapy. Enhan-
cing glycolytic flux while depleting metabolites from the
pentose phosphate pathway should cause irreversible cel-
lular damage due to increased ROS accumulation. It willtherefore be interesting to evaluate whether systemic in-
hibition of the FBPase-2 activity of PFKFB4 will provide
antitumor efficacy in different types of cancer.
Conclusions
We are gaining significant knowledge about the function
and regulation of PFK-2/FBPase-2 enzymes in cancer cells.
Allosteric regulation of glycolysis by Fru-2,6-P2 allows
cancer cells to precisely balance their glycolytic flux to ful-
fill their bioenergetics and biosynthetic demands. Disrup-
ting this balance is likely to limit the capacity of cancer
cells to adapt to the metabolic constraints imposed by the
tumor microenvironment. However, further research into
their expression, their relative activities, mechanisms of
allosteric regulation, localization and post-translational
modification is required to fully understand the role of
these enzymes in cancer metabolism. Moreover, another
level of complexity could be added and functions unre-
lated to glycolysis could be attributed to these enzymes in
cancer. Despite these open questions, the evidence accu-
mulated to date suggests that PFK-2/FBPase-2 enzymes
could be attractive targets for cancer treatment.
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